


Author's Accepted Manuscript

Cancer prevalence in men and women with schizophrenia

Nirit Agay, Natalie Flaks-Manov, Uri Nitzan, Moshe B. Hoshen, Levkovitz Yeheal, Hanan Munitz



PII: S0165-1781(17)30123-3
DOI: <http://dx.doi.org/10.1016/j.psychres.2017.07.082>
Reference: PSY10745

To appear in: *Psychiatry Research*

Received date: 22 January 2017
Revised date: 8 June 2017
Accepted date: 29 July 2017

Cite this article as: Nirit Agay, Natalie Flaks-Manov, Uri Nitzan, Moshe B. Hoshen, Levkovitz Yeheal and Hanan Munitz, Cancer prevalence in men and women with schizophrenia, *Psychiatry Research*, <http://dx.doi.org/10.1016/j.psychres.2017.07.082>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cancer prevalence in men and women with schizophrenia

Nirit Agay, PhD^{d*}; Natalie Flaks-Manov, MPH^a; Uri Nitzan, MD^{c,e}; Moshe B.

Hoshen, PhD^a; Levkovitz Yeheal, MD^{c,e}; Hanan Munitz, MBBS MRCPsych^b

^a Clalit Research Institute, Israel.

^bPublic Health Department, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel.

^c Shalvata Mental Health Center, Hod-Hasharon, Israel.

^d The Academic College of Tel Aviv-Yaffo, Tel-Aviv, Israel.

^eSackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.

*Corresponding Author: The Academic College of Tel Aviv-Yaffo, Rabenu

Yeruham St., Tel-Aviv Yaffo 86162, Israel. Mobile: 972-50-6461944, Fax: 972-3-6802770. niritaga@mta.ac.il

Abstract

The aim of this cross-sectional study was to compare cancer prevalence rates among patients with schizophrenia to those of the non-schizophrenia population. The study population included members of Clalit Health Services aged 25 to 74 years and all data was taken from patients' electronic health records. All-type cancer prevalence rates were calculated for both schizophrenia and non-schizophrenia populations across three age groups and gender. Age-adjusted rates of all-type cancer and of specified cancers were calculated for both populations. Of the 2,060,314 members who were included in the study, 32,748 had a diagnosis of schizophrenia. Cancer prevalence rates in women with and without schizophrenia were 491 per 10,000 and 439 per 10,000, respectively; in men, cancer prevalence rates were 226 per 10,000 and 296 per 10,000, respectively. The age-adjusted prevalence rate of all-type cancer

Download English Version:

<https://daneshyari.com/en/article/6812081>

Download Persian Version:

<https://daneshyari.com/article/6812081>

[Daneshyari.com](https://daneshyari.com)